December 08, 2025
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company’s mass spectrometry services to develop a new assay at the company’s facilities in Frankfurt, Germany in anticipation of starting a new clinical trial programme next year.